First-in-class drug approvals vs Clinical trial registrations in China
In 2025, first-in-class drug approvals in China stood at 11, against 5,215 for clinical trial registrations.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
First-in-class drug approvals and Clinical trial registrations
Unit: count · 8 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| First-in-class drug approvals | 2025 | Actual | 11 |
| First-in-class drug approvals | 2024 | Actual | 48 |
| First-in-class drug approvals | 2023 | Actual | 40 |
| First-in-class drug approvals | 2022 | Actual | 21 |
| Clinical trial registrations | 2025 | Actual | 5,215 |
| Clinical trial registrations | 2023 | Actual | 4,300 |
| Clinical trial registrations | 2022 | Actual | 3,410 |
| Clinical trial registrations | 2021 | Actual | 3,358 |
Shared periods
Side by side
Only 3 periods are published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
First-in-class drug approvals
Number of approved therapeutic drugs featuring a novel biological mechanism of action.
4 observations in China · source organisations: NMPA, NHSA
Clinical trial registrations
Number of clinical trials registered on the International Clinical Trials Registry Platform.
4 observations in China · source organisations: State Council, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring